Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter N Morcos

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Current Pharmacology Reports|March 7, 2017
Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current OpportunitiesStephen Fowler, Peter N Morcos, Yumi Cleary, et al.
Hepato-Gastroenterology|April 28, 2015
Induction dosing of peginterferon alfa-2a (40 KD) and/or high-dose ribavirin in genotype 1 CHC patients with difficult-to-treat characteristics: pharmacokinetic and viral kinetic (PK/VK) assessment from PROGRESSPeter N Morcos, Ruby Leong, James A Thommes, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 21, 2021
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancerJoy C Hsu, Felix Jaminion, Elena Guerini, et al.
Antimicrobial Agents and Chemotherapy|April 4, 2012
Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitorsMicaela B Reddy, Peter N Morcos, Sophie Le Pogam, et al.
Pharmacotherapy|August 16, 2013
Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapySebastian A Moreira, Peter N Morcos, Mercidita T Navarro, et al.
Bioanalysis|June 23, 2016
Bioanalysis of alectinib and metabolite M4 in human plasma, cross-validation and impact on PK assessmentKatja Heinig, Kazuhiro Miya, Tomonori Kamei, et al.
Clinical Pharmacology and Therapeutics|December 12, 2017
Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical DevelopmentYumi Cleary, Michael Gertz, Peter N Morcos, et al.
Addiction Biology|June 16, 2009
Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapyCandice Jamois, Patrick Smith, Royce Morrison, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 3, 2013
Two-way interaction study between ritonavir boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjectsPeter N Morcos, Linda Chang, Mercidita Navarro, et al.
Cancer Chemotherapy and Pharmacology|May 12, 2018
Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancerPeter N Morcos, Eveline Nueesch, Felix Jaminion, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Current Pharmacology Reports|March 7, 2017
Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current OpportunitiesStephen Fowler, Peter N Morcos, Yumi Cleary, et al.
Hepato-Gastroenterology|April 28, 2015
Induction dosing of peginterferon alfa-2a (40 KD) and/or high-dose ribavirin in genotype 1 CHC patients with difficult-to-treat characteristics: pharmacokinetic and viral kinetic (PK/VK) assessment from PROGRESSPeter N Morcos, Ruby Leong, James A Thommes, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 21, 2021
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancerJoy C Hsu, Felix Jaminion, Elena Guerini, et al.
Antimicrobial Agents and Chemotherapy|April 4, 2012
Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitorsMicaela B Reddy, Peter N Morcos, Sophie Le Pogam, et al.
Pharmacotherapy|August 16, 2013
Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapySebastian A Moreira, Peter N Morcos, Mercidita T Navarro, et al.
Bioanalysis|June 23, 2016
Bioanalysis of alectinib and metabolite M4 in human plasma, cross-validation and impact on PK assessmentKatja Heinig, Kazuhiro Miya, Tomonori Kamei, et al.
Clinical Pharmacology and Therapeutics|December 12, 2017
Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical DevelopmentYumi Cleary, Michael Gertz, Peter N Morcos, et al.
Addiction Biology|June 16, 2009
Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapyCandice Jamois, Patrick Smith, Royce Morrison, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 3, 2013
Two-way interaction study between ritonavir boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjectsPeter N Morcos, Linda Chang, Mercidita Navarro, et al.
Cancer Chemotherapy and Pharmacology|May 12, 2018
Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancerPeter N Morcos, Eveline Nueesch, Felix Jaminion, et al.
Pageof 6